4242 Campus Point Court
Tocagen is developing first-in-class, broadly applicable product candidates for the treatment of cancer using our cancer-selective gene therapy platform built on retroviral replicating vectors, or RRVs, initially for patients with recurrent high grade glioma, or HGG.
Our broadly applicable product candidates are designed to activate a patient’s immune system against their own cancer from within.
At the core of our approach is a gene therapy platform that utilizes RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed.
Stock Symbol: TOCA
Stock Exchange: NASDAQ
This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
95 articles with Tocagen
Tocagen Presents Preliminary Data from Toca 6 Trial Supportive of Immune Activation in Patients with Advanced Solid Tumors at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Tocagen Inc. today is presenting data describing the tumor microenvironment and immunogenicity of Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine, extended-release) in patients with solid tumor malignancies at the International Cancer Immunotherapy Conference hosted by The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) in New York City.
Tocagen Inc. today announced that members of the leadership team will present at the following upcoming investor conferences in New York City
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis
Tocagen Inc. announced the Toca 5 pivotal Phase 3 trial continues without modification following a planned first interim analysis of data conducted by an Independent Data Monitoring Committee (IDMC)
-Strong execution of Toca 5 Phase 3 clinical trial with upcoming milestones on track- -Projected year-end 2018 cash position increased to approximately $70 million- [07-August-2018] SAN DIEGO, Aug. 7, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and b
Tocagen Inc. announced it will report its second quarter 2018 financial results and business progress on Tuesday, August 7, 2018, after the close of the U.S. financial markets.
Tocagen Closes Previously Announced License Agreement with ApolloBio to Develop and Commercialize Toca 511 & Toca FC in Greater China
Tocagen Inc. and Beijing Apollo Venus Biomedical Technology Limited announced the closing of an agreement providing ApolloBio with the exclusive right to develop and commercialize Toca 511 & Toca FC within the greater China region.
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy
In a preclinical study, Toca 521 reversed PD-1/PD-L1 mediated immune suppression
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its first quarter 2018 financial results and business progress on Thursday, May 10, 2018, after the close of the U.S. financial markets.
Tocagen Inc. licensed its Phase III stage candidate Toca 511 & Toca FC to ApolloBio .
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties; Upfront and near-term development milestones payments total up to $20 million
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced updated durable response data from the Phase 1 study involving patients with high-grade glioma who received Toca 511 & Toca FC at the time of surgical resection
Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018
Safety, tolerability, confirmation of vector deposition demonstrated with intravenous delivery of Toca 511
Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced preliminary data from the Toca 6 Phase 1 study in advanced solid tumors will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018, held April 14-18 in Chicago.
Tocagen Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2017.
Tocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of Glioma
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted orphan medicinal product (orphan drug) designation to Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine) for the treatment of patients with glioma, a type of brain tumor.
Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its fourth quarter and full year 2017 financial results and operational progress on Thursday, March 8, 2018, after the close of the U.S. financial markets.
Tocagen today announced it has been selected for addition to the NASDAQ Biotechnology Index, which will become effective prior to the open of U.S. markets on Monday, December 18, 2017.
Net loss was $10.0 million, or $0.50 per common share (basic and diluted), for the quarter ended September 30, 2017.
Tocagen today announced it will report its third quarter 2017 financial results and business progress on Wednesday, November 8, 2017, after the close of the U.S. financial markets.
Tocagen has updated the protocol of the ongoing clinical trial of Toca 511 & Toca FC for the treatment of recurrent high-grade glioma patients.